Soft Drugs

doi:10.1002/9781118407738.ch5

Back

Book chapter

Soft Drugs

Retrometabolic Drug Design and Targeting, pp.77-258

John Wiley & Sons, Inc

2012-10-05

DOI: https://doi.org/10.1002/9781118407738.ch5

Abstract

CADD

inactive metabolite–based for new/safe drugs

enzymatic hydrolysis for drug activation

SD as soft analogs, moieties and hydrolytic enzymes

active metabolite SDs, and pro‐soft prodrugs

This chapter contains sections titled: Enzymatic Hydrolysis Soft Drug Approaches Inactive Metabolite–Based Soft Drugs Soft Analogs Active Metabolite–Based Soft Drugs Activated Soft Drugs Pro‐Soft Drugs Computer‐Aided Design Soft Drugs: Summary References

Metrics

5 Record Views

Details

Title: Soft Drugs
Contributors: Nicholas Bodor (Editor) - Center for Drug Discovery, University of Florida, Gainesville, Florida, USA
Peter Buchwald (Editor) - Diabetes Research Institute and Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami, Miami, Florida, USA
Publication Details: Retrometabolic Drug Design and Targeting, pp.77-258
Publisher: John Wiley & Sons, Inc; Hoboken, NJ, USA
Number of pages: 182
Language: English
Resource Type: Book chapter
Record Identifier: 991031598912302976